Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Characteristics of primary biliary cirrhosis

Immunoglobin G3 antibodies to ▀-galactosidase of Lactobacillus delbrueckii cross-react with the major mitochondrial autoepitope and are characteristic of primary biliary cirrhosis, finds the latest issue of Hepatology.

News image

fiogf49gjkf04

The serological hallmark of primary biliary cirrhosis is the presence of pyruvate dehydrogenase complex E2 subunit antimitochondrial antibodies.

Anti-pyruvate dehydrogenase complex E2 antibodies cross-react specifically with mycobacterial hsp65.

Dr Diego Vergani and colleagues demonstrated that the motif SxGDL[ILV]AE shared by pyruvate dehydrogenase complex E2212-226 and hsp's is a cross-reactive target.

The research team found that this same motif is present only in ▀-galactosidase of Lactobacillus delbrueckii.

▀-galactosidase266-280 was found in 52% of antimitochondrial antibodies-positive patients
Hepatology

The team hypothesized that this homology would also lead to cross-reactivity.

The researchers tested the mimics via ELISA for reactivity and competitive cross-reactivity.

Sera was used from 100 antimitochondrial antibodies-positive and 23 antimitochondrial antibodies-negative primary biliary cirrhosis patients and 190 controls.

The team also tested an Escherichia coli pyruvate dehydrogenase complex E2 mimic that has been pathogenetically linked to primary biliary cirrhosis but lacks this motif.

The team found that anti- ▀-galactosidase266-280 of Lactobacillus delbrueckii antibodies were restricted to 57 % of antimitochondrial antibodies-positive patients.

The researchers noted that anti- ▀-galactosidase266-280 of Lactobacillus delbrueckii belonged to immunoglobulin G3.

The team also found that 12% of the controls had anti- ▀-galactosidase266-280 antibodies, mainly of the immunoglobin G4 subclass.

The researchers observed that Escherichia coli pyruvate dehydrogenase complex E2 reactivity was virtually absent.

▀-galactosidase266-280 or pyruvate dehydrogenase complex E2212-226 reactivity of the immunoglobin G3 isotype was found in 52% of antimitochondrial antibodies-positive patients vs 1 control.

The team confirmed, via competition ELISA, Lactobacillus delbrueckii ▀-galactosidase266-280 or pyruvate dehydrogenase complex E2212-226 reactivity was due to cross-reactivity.

The research team observed that antibody affinity for ▀-galactosidase266-280 was greater than for pyruvate dehydrogenase complex E2 mimics.

In addition, the team noted that preincubation of a multireactive serum with ▀-galactosidase266-280 reduced the inhibition of enzymatic activity by 40%.

However, only 12 % marginal effects or 2 % with no effect was observed in human or Escherichia coli pyruvate dehydrogenase complex E2 mimics.

Dr Vergani's team concludes, ôImmunoglobin G3 antibodies to ▀-galactosidase of Lactobacillus delbrueckii cross-react with the major mitochondrial autoepitope and are characteristic of primary biliary cirrhosis."

Hepatol 2005: 42(2): 458-65
25 July 2005

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohnĺs
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us